Searched for
LIRAGLUTIDE
Kiran Mazumdar-Shaw names niece Claire as successor, targets semaglutide push from FY28; debt cut to $1.1 billionBiocon's Executive Chairperson, Kiran Mazumdar-Shaw, outlined a five-year leadership transition with her niece, Claire Mazumdar, as success...- Biocon shifts focus to margins, capacity utilisation after expansion phaseBiocon is shifting its strategy to focus on capacity utilization, margin expansion, and improved returns after significant investments in g...
- Govt cracks down on GLP-1 drugs: Safety first amid weight-loss hypeIndia's government has released strict rules for GLP-1 drugs, used for diabetes and obesity. These powerful medications are now prescriptio...
- Biocon not to rush generic semaglutide to packed India market, says incoming CEO Shreehas TambeBiocon will delay its Indian launch of semaglutide. The company is focusing on international markets for the diabetes and weight-management...
- Liraglutide still a ‘decent market’ despite Novo’s price moves: Siddharth Mittal, BioconBiocon CEO Siddharth Mittal outlines the company's strategy in the competitive GLP-1 market. Focusing on liraglutide's launch in the US and...
- Biocon reports 95% YoY decline in net profit, operating revenue up 15%Biocon's Q1 net profit declined 95% year-on-year, but on a like-for-like basis, profit after tax increased by 65%. Revenue grew 15% to Rs 3...
- Eris Lifesciences eyes ‘good’ share in semaglutide generics, says COOEris Lifesciences plans to lead in generic semaglutide drugs. The patent for Novo Nordisk's drug expires in India in March 2026. Eris aims ...
- Biocon gets CDSCO nod for generic diabetes medicationBiocon has secured Indian regulatory approval for its generic Liraglutide drug substance and product, a version of Victoza, for treating Ty...
- Biocon shares in focus after CDSCO nod for diabetes drug LiraglutideBiocon shares are in focus as the company has received regulatory approval from the Central Drugs Standard Control Organisation for its dia...
- Biocon launches diabetes, obesity management drug in UKBiocon has launched Liraglutide, a drug for diabetes and obesity management, in the UK under the brand names Liraglutide Biocon and Biolide...
- How is India transforming the global biopharma landscape?In 2024, India's biopharma sector marked notable achievements, with approvals of key biosimilars and the launch of advanced CAR-T therapy. ...
- Biocon, Zentiva get EU approval for generic diabetes, weight management drugBiocon Ltd and Zentiva have secured decentralised procedure approval in the EU for Liraglutide, a complex formulation used for diabetes and...
- Biocon inks licensing, supply pact with South Korea's Handok for chronic weight management productBiocon signs exclusive licensing agreement with Handok for commercialisation of synthetic Liraglutide in South Korea, expanding portfolio t...
- Biocon inks supply, distribution pact with Medix for chronic weight management drug in MexicoBiocon partners with Medix to distribute Liraglutide for chronic weight management in Mexico, offering affordable obesity treatment options...
- Weight-loss medicines: Biocon eyes a $100 billion jackpot with weighty pivotWeight-loss drugs: Biocon Ltd. is shifting focus to anti-obesity therapies as patents for key medications expire, leading to a surge in gen...
- Glenmark launches antidiabetic drug in IndiaThe drug is being marketed under the brand name Lirafit following the approval from the Drug Controller General of India (DCGI), the compan...
- New drug can treat type 2 diabetes for children under age 18Currently only two drugs, metformin and insulin, are approved for the treatment of diabetes in children.
- Sajjala Bio to begin clinical trials on diabetes drugIn a statement, the Hyderabad-based company that reported Rs 15 crore of revenue last fiscal year, said it would soon take up clinical stud...
- Scientists offer hope for genetically determined obesityLondon, June 3 (IANS) Unable to maintain weight loss due to your genetic predisposition to obesity? Take heart, an injectable drug widely u...
- Novo to launch anti-diabetes drug in India by 2010Danish pharmaceutical company Novo Nordisk plans to launch its anti-diabetes drug Liraglutide in India by 2010. The company claims that the...
Load More
